

July 08, 2002 1 min read

Allergan to focus on Alphagan-P, discontinue Alphagan

IRVINE, Calif. — Because of physicians' acceptance of the glaucoma drug Alphagan P, Allergan will discontinue U.S. distribution of its older formulation, Alphagan, the company announced last week.

Alphagan P (brimonidine) 0.15% is comparable in efficacy to Alphagan 0.2%, but is preserved with Purite. Company officials said their research has shown that "a vast majority" of its physician customers prefer this newer formulation brimonidine over the older version that did not have the Purite preservative. Clinical trials have shown patients who receive Alphagan P have lower rates of certain adverse events (such as ocular allergy) than patients receiving Alphaga

Read next

[Proficiency, flexibility help match patients with appropriate MIGS device](#)

[Three studies affirm efficacy, safety of brolucizumab in DME](#)

Both drugs are indicated for lowering intraocular pressure in patients with open-angle glaucoma and ocular hypertension.

February 08, 2022 1 min read

TearClear initiates phase 3 trial of preservative-free latanoprost

TearClear has initiated a phase 3 trial evaluating TC-002, a preservative-free latanoprost ophthalmic solution, in patients with glaucoma, according to a press release.

The prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 3-month CLEAR study investigating the ocular hypotensive efficacy and safety of TC-002 (preservative-free latanoprost ophthalmic solution 0.005%) compared with latanoprost ophthalmic solution 0.005%.

CONTINUE READING